Interleukin-12 as a veterinary vaccine adjuvant
This disclosure describes a composition for enhancing the immunogenicity of a veterinary vaccine that comprises a pharmacologically effective amount of an immunomodulator and an immunoadjuvant. Additionally, the disclosure describes a vaccine composition comprising an effective immunizing amount of an antigen, an immunomodulator, an immunoadjuvant and a pharmaceutically acceptable carrier. The compositions may optionally contain conventional, secondary adjuvants or preservatives. The disclosure further describes a unique method for enhancing or accelerating the immunogenicity of weak, immunosuppressive or marginally safe antigens by administering to an avian or mammalian species a pharmacologically effective amount of the aforesaid immunogenicity enhancing composition or an effective immunizing amount of the aforesaid vaccine composition.
1 - 17 . (canceled)
18 . An improved veterinary vaccine composition which comprises an effective immunizing amount of Streptococcus equi antigen, interleukin-12, an immunoadjuvant and a pharmaceutically acceptable carrier.
19 - 21 . (canceled)
22 . The vaccine composition according to claim 18 , wherein the interleukin-12 is a homologous animal, recombinant human or recombinant murine interleukin-12.
23 . The vaccine composition according to claim 22 , wherein the immunoadjuvant is selected from the group consisting of a saponin, a metabolizable oil, a block copolymer, an ethylene/maleic copolymer, an acrylic acid copolymer, an acrylic acid copolymer emulsion, a mineral oil emulsion and a mixture thereof.
24 . The vaccine composition according to claim 23 , wherein the immunoadjuvant is saponin.
25 . The vaccine composition according to claim 23 , wherein the metabolizable oil is squalene or squalane.
26 . (canceled)
27 . The vaccine composition according to claim 23 , wherein the block copolymer is a polyoxypropylene-polyoxyethylene block copolymer.
28 - 41 . (canceled)
42 . The vaccine composition according to claim 18 , further comprising a preservative.
43 . The vaccine composition according to claim 18 , further comprising a secondary adjuvant.
44 . The vaccine composition according to claim 43 , wherein the secondary adjuvant is selected from the group consisting of a stabilizer, an emulsifier, aluminum hydroxide, aluminum phosphate, a pH adjuster, a surfactant, a liposome, an iscom adjuvant, a synthetic glycopeptide, an extender, carboxypolymethylene, bacterial cell wall, a derivative of a bacterial cell wall, vaccinia, an animal poxvirus protein, a subviral particle adjuvant, cholera toxin, N,N-dioctadecyl-N′,N′-bis(2-hydroxyethyl)propanediamine, monophosphoryl lipid A, dimethyldioctadecyl-ammonium bromide and a mixture thereof.
45 . (canceled)
46 . A method for potentiating, accelerating or extending the immunogenicity of a weak, immunosuppressive or marginally safe Streptococcus equi antigen which comprises administering to a horse an effective immunizing amount of the vaccine composition according to claim 18 .
47 . The method according to claim 6 , which comprises administering the vaccine composition subcutaneously, intramuscularly, intradermally, intraperitoneally, intranasally, intrabuccally, transdermally or orally.
48 . A method for potentiating, accelerating or extending the immunogenicity of a weak, immunosuppressive or marginally safe Streptococcus equi antigen which comprises administering to a horse an effective immunizing amount of the vaccine composition according to claim 24 .
49 - 51 . (canceled)
52 . A method for vaccinating a horse against Strangles or infection with Streptococcus equi which comprises administering to the horse an effective immunizing amount of the vaccine composition according to claim 18 .
53 . The method according to claim 52 , which comprises administering the vaccine composition intranasally.
54 . A method for vaccinating a horse against Strangles or infection with Streptococcus equi which comprises administering to the horse an effective immunizing amount of the vaccine composition according to claim 24 .
55 . The method according to claim 54 , which comprises administering the vaccine composition intranasally.